TORONTO, April 02, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:MBX) (Microbix®), an innovator of
biological products and technologies, announces the voting results from the Annual and Special Meeting of Shareholders (the
“Meeting”) that was held on March 28, 2018.
At the Meeting, 42.78% of the issued and outstanding shares were represented. A majority of shareholders voted
in favour of all resolutions brought before the Meeting. Details of all resolutions that were voted upon are set out in the
Management Information Circular (the “Circular”) dated February 9, 2018. The Circular is available on the Company’s website
(www.microbix.com) and on SEDAR (www.sedar.com).
All of the board of directors nominees listed in the Circular were re-elected as directors of Microbix. Results
of the vote were as follows:
| Nominee |
Votes For |
% Votes For |
Withheld |
% Withheld |
| Peter M. Blecher |
36,562,282 |
99.95 |
% |
19,200 |
0.05 |
% |
| Mark A. Cochran |
36,559,982 |
99.94 |
% |
21,500 |
0.06 |
% |
| Vaughn C. Embro-Pantalony |
36,467,482 |
99.69 |
% |
114,000 |
0.31 |
% |
| William J. Gastle |
36,463,782 |
99.68 |
% |
117,700 |
0.32 |
% |
| Cameron L. Groome |
36,464,782 |
99.68 |
% |
116,700 |
0.32 |
% |
| Martin Marino |
36,562,282 |
99.95 |
% |
19,200 |
0.05 |
% |
| Joseph D. Renner |
36,560,982 |
99.94 |
% |
20,500 |
0.06 |
% |
In addition, shareholders also approved a resolution re-appointing the Company’s auditors, Ernst & Young LLP
with 99.93% of the votes cast in favour, the adoption of a new 10% rolling stock option plan in replacement of the Company’s
existing fixed number stock option plan with 95.20% of the votes cast in favour of; and amendments to certain warrants held by an
Insider of the Company with 88.56% of the disinterested votes cast in favour.
The slides of management’s presentation at the Meeting have been posted at www.microbix.com
About Microbix Biosystems Inc.
Microbix specializes in developing proprietary biological and technology solutions for human health and
well-being. It manufactures a wide range of critical biological materials for the global diagnostics industry, notably antigens
used in immunoassays or quality assessment products. Microbix’ products are sold to more than 100 customers worldwide, primarily to
multinational diagnostics companies and laboratory accreditation organizations.
Microbix also applies its biological expertise and infrastructure to create proprietary new products and
technologies. Currently it is commercializing two such products, (1) Kinlytic® urokinase, a biologic thrombolytic drug used to
treat blood clots and (2) LumiSort™ cell-sorting, a technology platform for ultra-rapid and efficient sorting of somatic cells that
can be used to enrich cell populations of interest, such as in sexing semen. Established in 1988, Microbix is a publicly traded
company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada.
Forward-Looking Information
This news release includes “forward-looking information,” as such term is defined in applicable securities laws.
Forward-looking information includes, without limitation, discussion of financial results or the outlook for the business, risks
associated with its financial results and stability, its biologicals business, development projects such as those referenced
herein, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity
and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital
on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are
not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not
guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual
performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual
future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or
implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s
judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking
information.
Please visit www.microbix.com or www.sedar.com for recent Microbix filings.
For further information, please contact:
Cameron Groome, CEO
(905) 361-8910 |
Jim Currie, CFO
(905) 361-8910 |
Deborah Honig, Investor Relations
Adelaide Capital Markets
(647) 203-8793 ir@microbix.com |
Copyright © 2018 Microbix Biosystems Inc. Microbix®,
Kinlytic® and LumiSort™ are trademarks of the Company
